Overview
Candidal endocarditis is a rare but severe infection of the heart valves or endocardium caused by Candida species, often complicating underlying conditions such as esophageal rupture (Boerhaave's syndrome). The prognosis is typically poor without prompt and accurate management 1.Diagnosis
Clinical Presentation: Fever, heart murmur, embolic events, and signs of heart failure 1.
Laboratory Tests: Blood cultures are crucial but may be negative in up to 50% of cases; consider repeat cultures 1.
Imaging: Echocardiography (transthoracic or transesophageal) essential for visualizing vegetations and assessing valve function 1.
Serological Methods: New serological techniques can aid in guiding antifungal therapy and monitoring treatment response 1.Management
First-Line Treatment: Amphotericin B or echinocandins (e.g., micafungin) are recommended for severe cases 1.
Adjunctive Therapy: Surgical intervention may be necessary for valve replacement in cases of persistent infection or valvular damage 1.
Duration: Treatment duration often extends beyond 4-6 weeks, guided by clinical response and microbiological data 1.Special Populations
Comorbidities: Patients with esophageal rupture (Boerhaave's syndrome) have significantly increased risk and poor prognosis 1.Key Recommendations
Utilize echocardiography for definitive diagnosis and monitoring of candidal endocarditis 1 (Evidence: Strong).
Employ new serological methods to guide antifungal therapy and assess treatment efficacy 1 (Evidence: Moderate).
Consider surgical intervention for persistent infection or valvular dysfunction despite medical management 1 (Evidence: Expert opinion).References
1 de Belder MA, Walker JD, Burnie JP, Rothman MT. Survival after rupture of the oesophagus and subsequent candidal endocarditis: use of new serological methods in management. European heart journal 1989. link